Healthcare and Life Sciences
How we can help
Our extensive array of services are tailored to the specific needs of the healthcare and life sciences sector. This includes capital raising, mergers and acquisitions, competition and consumer guidance, intellectual property and patents, disputes and investigations and Therapeutic Goods Regulations. We act for government departments, agencies, and research bodies, as well as private equity investors, health and life sciences corporations, venture capital firms and private health insurers.
We give you an edge in unlocking opportunities, with a special focus on:
pharmaceuticals, life sciences, and biotech: (Research and development, clinical trials, TGA compliance, manufacturing and regulatory affairs)
healthcare facilities and services: (Private and public hospitals, medical and dental practices, radiology, medical centres, aged care/NDIS and veterinary)
medtech and digital health platforms: (Artificial intelligence in healthcare technology and regulatory compliance)
aged care and National Disability Insurance Scheme (NDIS) support
medical, surgical and healthcare products: (Manufacturing and quality assurance, TGA compliance, logistics and distribution, retail and marketing).
Healthcare and Life Sciences experience
Sigma Healthcare
On its merger with Chemist Warehouse Group. This merger will create Australia’s largest pharmacy group, with an expected market capitalisation of $8.8 billion.
Integrated Clinical Oncology Network
On the $2.4 billion acquisition of Icon Group by EQT.
Ozempic
On IP and regulatory advice to a leading health services business on ground breaking weight loss medications.
harrison.ai
On a joint venture with Sonic Healthcare to commercialise AI solutions in pathology.
Virtus Health
In court proceedings for breach of contract and misleading and deceptive conduct in relation to faulty ventilators supplied during the COVID-19 pandemic.
Health Administration (NSW Health)
In court proceedings for breach of contract and misleading and deceptive conduct in relation to faulty ventilators supplied during the COVID-19 pandemic.
Viatris (formerly Mylan)
On the merger and competition compliance with Pfizer’s Upjohn division, creating a US$12 billion pharmaceutical giant.
Qscan Group
On Infratil’s acquisition of up to 60% of Qscan Group, a prominent Australian diagnostic imaging practice, from Quadrant Private Equity and existing shareholders.
Resmed
On multi-jurisdiction and high-stakes patent litigation addressing patent infringement allegations by Fisher & Paykel in Australia, the US, Germany and New Zealand.